Renata G F Alvim

Prof. Dr. Renata G F Alvim

Federal University of Rio de Janeiro, Rio de Janeiro, Brazil
orcid

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
22 July 2021 in Journal of Experimental Medicine
Verified
Journal Article
Open access
PDF file
CCCecilia B. Cavazzoni
Cecilia B. Cavazzoni
VBVicente B.T. Bozza
Vicente B.T. Bozza
TLTostes C.V. Lucas
Tostes C.V. Lucas
LCLuciana Conde
Luciana Conde
BMBruno Maia
Bruno Maia
AVAndre M. Vale
Andre M. Vale
Besides antigen-specific responses to viral antigens, humoral immune response in virus infection can generate polyreactive and autoreactive antibodies. Dengue and Zika virus infections have been linked to antibody-mediated autoimmune disorders, including Guillain-Barré syndrome. A unique feature of flaviviruses is the secretion of nonstructural protein 1 (NS1) by infected cells. NS1 is highly immunogenic, and antibodies targeting NS1 can have both protective and pathogenic roles. In the present study, we investigated the humoral immune response to Zika virus NS1 and found NS1 to be an immunodominant viral antigen associated with the presence of autoreactive antibodies. Through single B cell cultures, we coupled binding assays and BCR sequencing, confirming the immunodominance of NS1. We demonstrate the presence of self-reactive clones in germinal centers after both infection and immunization, some of which present cross-reactivity with NS1. Sequence analysis of anti-NS1 B cell clones showed sequence features associated with pathogenic autoreactive antibodies. Our findings demonstrate NS1 immunodominance at the cellular level as well as a potential role for NS1 in ZIKV-associated autoimmune manifestations.

18 June 2021 in Biotechnology and Bioengineering
Verified
Journal Article
Closed access
PDF file
RARenata G F Alvim
Renata G F Alvim
TLTúlio M. Lima
Túlio M. Lima
JSJerson Silva
Jerson Silva
GOGuilherme de Oliveira
Guilherme de Oliveira
LCLeda R. Castilho
Leda R. Castilho

15 July 2020 in medRxiv
Verified
Preprint
Open access
PDF file
RARenata G F Alvim
Renata G F Alvim
TLTulio M. Lima
Tulio M. Lima
DRDanielle A. S. Rodrigues
Danielle A. S. Rodrigues
FMFederico Francisco Marsili
Federico Francisco Marsili
VBVicente B. T. Bozza
Vicente B. T. Bozza
AVAndré M. Vale
André M. Vale
Accurate serological tests are essential tools to allow adequate monitoring and control of COVID-19 spread. Production of a low-cost and high-quality recombinant viral antigen can enable the development of reliable and affordable serological assays, which are urgently needed to facilitate epidemiological surveillance studies in low-income economies. Trimeric SARS-COV-2 spike (S) protein was produced in serum-free, suspension-adapted HEK293 cells. Highly purified S protein was used to develop an ELISA, named S-UFRJ test. It was standardized to work with different types of samples: (i) plasma or serum from venous blood samples; (ii) eluates from dried blood spots (DBS) obtained by collecting blood drops from a finger prick. We developed a cost-effective, scalable technology to produce S protein based on its stable expression in HEK293 cells. Using this recombinant antigen, we presented a workflow for test development in the setting of a pandemic, starting from limited amounts of samples up to reaching final validation with hundreds of samples. Test specificity was determined to be 98.6%, whereas sensitivity was 95% for samples collected 11 or more days after symptoms onset. A ROC analysis allowed optimizing the cut-off and confirming the high accuracy of the test. Endpoint titers were shown to correlate with virus neutralization assessed as PRNT90. There was excellent agreement between plasma and DBS samples, significantly simplifying sample collection, storing, and shipping. An overall cost estimate revealed that the final retail price could be in the range of one US dollar. The S-UFRJ assay developed herein meets the quality requirements of high sensitivity and specificity. The low cost and the use of mailable DBS samples allow for serological surveillance and follow-up of SARS-CoV-2 vaccination of populations regardless of geographical and socio-economic aspects. We hope the detailed guidelines for the development of an affordable and accurate anti-spike SARS-COV-2 ELISA, such as S-UFRJ described here, will stimulate governmental and non-governmental health agencies in other countries to engage in much-needed large-scale studies monitoring the spread and immunity to SARS-COV-2 infection.

18 August 2020 in bioRxiv
Verified
Preprint
Open access
PDF file
LCLuis Eduardo Ribeiro da Cunha
Luis Eduardo Ribeiro da Cunha
ASAdilson A. Stolet
Adilson A. Stolet
MSMarcelo Abrahão Strauch
Marcelo Abrahão Strauch
VPVictor Augusto Augusto Roncaglia Roncaglia Pereira
Victor Augusto Augusto Roncaglia Roncaglia Pereira
CDCarlos H. Dumard
Carlos H. Dumard
JSJerson Silva
Jerson Silva
We used the trimeric spike (S) glycoprotein (residues 1-1208) in the prefusion conformation to immunize horses for production of hyperimmune globulins against SARS-CoV-2. Serum antibody titers measured by anti-spike ELISA were above 1:1,000,000, and neutralizing antibody titer was 1:14,604 (average PRNT 90 ), which is 140-fold higher than the average neutralizing titer of plasma from three convalescent COVID-19 patients analyzed for comparison. Using the same technology routinely used for industrial production of other horse hyperimmune products, plasma from immunized animals was pepsin digested to remove the Fc portion and purified, yielding a F(ab’) 2 preparation with PRNT 90 titers 150-fold higher than the neutralizing titers in human convalescent plasma. Repeating the hyperimmunization in a second group of horses confirmed the very high neutralizing titers in serum and in a GMP clinical F(ab’) 2 lot. Virus-neutralizing activity in samples from mice that received the F(ab’) 2 preparation was detected even three days after injection, indicating an appropriate half-life for therapeutic intervention. These results supported the design of a clinical trial (identifier NCT04573855 ) to evaluate safety and efficacy of this horse F(ab’) 2 preparation.

12 August 2022 in Vaccines
Verified
Journal Article
Open access
PDF file
LFLuan Firmino-Cruz
Luan Firmino-Cruz
JSJúlio Souza dos Santos
Júlio Souza dos Santos
AFAlessandra Marcia Da Fonseca-Martins
Alessandra Marcia Da Fonseca-Martins
DODiogo Oliveira-Maciel
Diogo Oliveira-Maciel
GGGustavo Guadagnini-Perez
Gustavo Guadagnini-Perez
HGHerbert L. de Matos Guedes
Herbert L. de Matos Guedes
Despite the intramuscular route being the most used vaccination strategy against SARS-CoV-2, the intradermal route has been studied around the globe as a strong candidate for immunization against SARS-CoV-2. Adjuvants have shown to be essential vaccine components that are capable of driving robust immune responses and increasing the vaccination efficacy. In this work, our group aimed to develop a vaccination strategy for SARS-CoV-2 using a trimeric spike protein, by testing the best route with formulations containing the adjuvants AddaS03, CpG, MPL, Alum, or a combination of two of them. Our results showed that formulations that were made with AddaS03 or CpG alone or AddaS03 combined with CpG were able to induce high levels of IgG, IgG1, and IgG2a; high titers of neutralizing antibodies against SARS-CoV-2 original strain; and also induced high hypersensitivity during the challenge with Spike protein and a high level of IFN-γ producing CD4+ T-cells in mice. Altogether, those data indicate that AddaS03, CpG, or both combined may be used as adjuvants in vaccines for COVID-19.

5 October 2025 in International Journal of Pharmaceutics
Verified
Journal Article
Open access
MAMaximilian Aisenstat
Maximilian Aisenstat
KDKelvin Duong
Kelvin Duong
CRChristina Renshaw
Christina Renshaw
RKRobert Kinsey
Robert Kinsey
KKKyle Kaufman
Kyle Kaufman
RVReinhard Vehring
Reinhard Vehring
A nasal dry powder adjuvanted subunit COVID vaccine candidate was manufactured via spray drying and evaluated for physicochemical stability and aerosol performance over the course of 10 months under accelerated conditions. A nanoliposomal adjuvant system containing synthetic TLR 4 agonist GLA and synthetic TLR 7/8 agonist 3 M-052 and a trimeric SARS-CoV-2 spike protein antigen were encapsulated using trehalose and varying amounts of trileucine as excipients. 1 % and 3 % trileucine batches as well as a trehalose-only control batch were spray dried to achieve varying levels of particle surface modification and to study the overall effects on stability and aerosol performance. All batches achieved good yields and low processing losses on drying. Samples were held at 25 °C and 40 °C and monitored for physical and chemical stability. All three batches showed excellent performance over the course of the study. Overall morphology; solid phase; moisture content; contents of GLA and 3 M-052; and aerosol performance were largely maintained after exposure to high temperatures for 10 months. Spike protein antigen remained present in all samples after exposure, and liposomal size distributions remained within acceptable ranges for all but one of the samples. Overall, this vaccine candidate showed performance suitable for distribution independent of the cold chain and would be able to withstand high-temperature conditions encountered during last-mile delivery.